BIOMAT Database Logo BIOMAT Database Logo

Neoral reduces the incidence of acute rejection after renal transplantation. 1998

S Sandrini, and G Setti, and P Gaggia, and R Chiappini, and R Maffeis, and R Tardanico, and R Maiorca
Institute of Nephrology, University and Spedali Civili, Brescia, Italy.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006650 Histocompatibility Testing Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed) Crossmatching, Tissue,HLA Typing,Tissue Typing,Crossmatchings, Tissue,HLA Typings,Histocompatibility Testings,Testing, Histocompatibility,Testings, Histocompatibility,Tissue Crossmatching,Tissue Crossmatchings,Tissue Typings,Typing, HLA,Typing, Tissue,Typings, HLA,Typings, Tissue
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates

Related Publications

S Sandrini, and G Setti, and P Gaggia, and R Chiappini, and R Maffeis, and R Tardanico, and R Maiorca
Low incidence of acute cellular rejection in liver transplantation with Neoral.
August 1998, Transplantation proceedings,
S Sandrini, and G Setti, and P Gaggia, and R Chiappini, and R Maffeis, and R Tardanico, and R Maiorca
Low incidence of rejection after synchronous pancreas-kidney transplantation with Neoral.
August 1998, Transplantation proceedings,
S Sandrini, and G Setti, and P Gaggia, and R Chiappini, and R Maffeis, and R Tardanico, and R Maiorca
Neoral in acute renal transplantation.
July 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
S Sandrini, and G Setti, and P Gaggia, and R Chiappini, and R Maffeis, and R Tardanico, and R Maiorca
Reduced acute rejection after liver transplantation with Neoral-based triple immunosuppression.
March 1997, Lancet (London, England),
S Sandrini, and G Setti, and P Gaggia, and R Chiappini, and R Maffeis, and R Tardanico, and R Maiorca
Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression.
August 1998, Transplantation proceedings,
S Sandrini, and G Setti, and P Gaggia, and R Chiappini, and R Maffeis, and R Tardanico, and R Maiorca
Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation.
August 1998, Transplantation,
S Sandrini, and G Setti, and P Gaggia, and R Chiappini, and R Maffeis, and R Tardanico, and R Maiorca
Sirolimus (rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: an initial experience in Taiwan.
September 2004, Transplantation proceedings,
S Sandrini, and G Setti, and P Gaggia, and R Chiappini, and R Maffeis, and R Tardanico, and R Maiorca
Acute rejection after living donor renal transplantation.
August 1994, Transplantation proceedings,
S Sandrini, and G Setti, and P Gaggia, and R Chiappini, and R Maffeis, and R Tardanico, and R Maiorca
Basiliximab decreases the incidence of acute rejection after intestinal transplantation.
May 2002, Transplantation proceedings,
S Sandrini, and G Setti, and P Gaggia, and R Chiappini, and R Maffeis, and R Tardanico, and R Maiorca
Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
September 1998, Kidney international,
Copied contents to your clipboard!